Cardiac surgery devices keep millions of hearts beating, from valve replacements to bypass support, and the same cardiac surgery device companies lead the market year after year. iData Research valued the global market at $21.1 billion in 2025 and is forecast to grow at a 5.5% CAGR to reach $30.8 billion. This guide ranks the three leaders and explains what keeps each ahead.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who are the top cardiac surgery device companies in 2026
➜ Why Abbott leads the cardiac surgery device market
➜ What makes Edwards Lifesciences a top cardiac surgery device company
➜ Why Medtronic ranks among the top cardiac surgery device companies
➜ How big is the cardiac surgery device market in 2026
Key Takeaways
- Abbott, Edwards Lifesciences, and Medtronic are the top 3 cardiac surgery device companies in 2026.
- Abbott ranks first, Edwards Lifesciences second, and Medtronic third by 2025 market share.
- The global market was worth $21.1 billion in 2025 and is heading toward $30.8 billion by 2032.
- Abbott and Medtronic carry the broadest portfolios, while Edwards leads through its transcatheter valve franchise.
- Aging populations, rising cardiovascular disease, and a shift to minimally invasive procedures drive growth.
Who are the top cardiac surgery device companies in 2026?
The three largest cardiac surgery device companies by market share in 2025 were Abbott, Edwards Lifesciences, and Medtronic. They lead a large and growing market. The global cardiac surgery device market reached $21.1 billion in 2025 and is projected to reach $30.8 billion by 2032, according to iData Research.
Abbott sits ahead of the field as the most broadly diversified player, competing across most cardiac surgery segments. Edwards Lifesciences follows, leading most of the segments it competes in through its transcatheter aortic valve franchise. Medtronic ranks third on the strength of one of the widest portfolios in the market. One pattern connects all three cardiac surgery device companies. Each leans on flagship product lines that clinicians trust, and each competes across both surgical and transcatheter approaches.
Why Abbott leads the cardiac surgery device market
Abbott is the top cardiac surgery device company because it is the most broadly diversified player in the market.
It held the leading overall position in 2025, competing across most cardiac surgery segments.
Recent approvals have strengthened its structural heart business.
In August 2025, Abbott’s Navitor transcatheter aortic valve implantation system received CE Mark approval for an expanded aortic stenosis indication.
In July 2025, its TriClip system gained regulatory approval in Japan.
That mix of scale and steady approvals keeps Abbott ahead year after year.
What makes Edwards Lifesciences a top cardiac surgery device company
Edwards Lifesciences ranks second and is anchored by its transcatheter aortic valve franchise.
It leads most of the structural heart segments it competes in.
In May 2025, the SAPIEN 3 transcatheter aortic valve replacement platform received FDA approval to treat asymptomatic patients with severe aortic stenosis.
That clearance widens the pool of eligible patients.
Edwards has stayed active in deal-making across transcatheter therapies.
In August 2025, the FTC moved to block its planned acquisition of JenaValve on antitrust grounds.
Why Medtronic ranks among the top cardiac surgery device companies
Medtronic holds the third spot with one of the broadest portfolios in the market.
Its range spans tissue and mechanical heart valves, annuloplasty repair, transcatheter heart valves, coronary bypass support, and preshaped guidewires.
The company launched its VitalFlow ECMO system and its next-generation Avalus Ultra surgical tissue valve in 2024.
In October 2025, Medtronic brought Avalus Ultra to India, expanding its surgical valve reach across the Asia-Pacific.
Continued product launches keep Medtronic firmly in the top tier.
How big is the cardiac surgery device market in 2026?
iData Research valued the global cardiac surgery device market at $21.1 billion in 2025, with a growth forecast at a 5.5% CAGR toward $30.8 billion.
Demand is rising as an aging population brings more patients with advanced heart disease.
A global rise in cardiovascular disease is expanding the treatable patient pool, and valvular heart disease alone affected an estimated 74 million people worldwide in 2019, as reported in a study published by the National Library of Medicine.
The shift toward minimally invasive and transcatheter procedures is widening treatment to higher-risk patients once ineligible for open surgery.
The report tracks the market across seven world regions, with competitive analysis presented for North America, Western Europe, and the rest of the world.
For related cardiovascular market leaders, see iData Research’s global interventional cardiology market report.
Frequently asked questions about cardiac surgery device companies
Who is the largest cardiac surgery device company in 2026?
Abbott is the largest. It ranked first in the global cardiac surgery device market in 2025, ahead of Edwards Lifesciences and Medtronic.
How big is the cardiac surgery device market?
iData Research valued the global cardiac surgery device market at $21.1 billion in 2025. It is expected to grow at a 5.5% CAGR to reach $30.8 billion by 2032.
Which company leads in transcatheter heart valves?
Edwards Lifesciences leads in transcatheter aortic valve replacement with its SAPIEN platform. Abbott competes with its Navitor system, and Medtronic competes across surgical and transcatheter valves.
What devices does cardiac surgery include?
Cardiac surgery devices include tissue and mechanical heart valves, transcatheter valve repair and replacement systems, coronary artery bypass support, ventricular assist devices, and ECMO systems.
For full rankings of the top cardiac surgery device companies, segment data, and market sizing, explore the iData Research global cardiac surgery device report.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
